Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

385 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Study of the overproduced uridine-diphosphate-N-acetylmuramate:L-alanine ligase from Escherichia coli.
Liger D, Masson A, Blanot D, van Heijenoort J, Parquet C. Liger D, et al. Among authors: masson a. Microb Drug Resist. 1996 Spring;2(1):25-7. doi: 10.1089/mdr.1996.2.25. Microb Drug Resist. 1996. PMID: 9158719
The UDP-MurNAc-L-alanine ligase was overproduced 2000-fold in a strain harboring a recombinant plasmid (pAM1005) with the murC gene under the control of the inducible promoter trc. The murC gene product appears as a 50-kDa protein accounting for ca. 50% of to …
The UDP-MurNAc-L-alanine ligase was overproduced 2000-fold in a strain harboring a recombinant plasmid (pAM1005) with the murC …
Site-directed mutagenesis and chemical modification of the two cysteine residues of the UDP-N-acetylmuramoyl:L-alanine ligase of Escherichia coli.
Nosal F, Masson A, Legrand R, Blanot D, Schoot B, van Heijenoort J, Parquet C. Nosal F, et al. Among authors: masson a. FEBS Lett. 1998 Apr 24;426(3):309-13. doi: 10.1016/s0014-5793(98)00364-0. FEBS Lett. 1998. PMID: 9600257
However, C230 played a role in enzyme stability and substrate binding. N-Ethylmaleimide alkylation led to monoalkylated and dialkylated proteins. ...
However, C230 played a role in enzyme stability and substrate binding. N-Ethylmaleimide alkylation led to monoalkylated and dialkylat …
Over-production, purification and properties of the uridine-diphosphate-N-acetylmuramate:L-alanine ligase from Escherichia coli.
Liger D, Masson A, Blanot D, van Heijenoort J, Parquet C. Liger D, et al. Among authors: masson a. Eur J Biochem. 1995 May 15;230(1):80-7. doi: 10.1111/j.1432-1033.1995.0080i.x. Eur J Biochem. 1995. PMID: 7601127
The murC gene product was visualized as a 50-kDa protein accounting for approximately 50% of the cell protein. A two-step purification led to 1 g of a homogeneous protein from an 18-1 culture. ...Under the optimal in vitro conditions a turnover number …
The murC gene product was visualized as a 50-kDa protein accounting for approximately 50% of the cell protein. A two-step puri …
Proton magnetic resonance investigation of the conformational properties of the basic pancreatic trypsin inhibitor.
Masson A, Wüthrich K. Masson A, et al. FEBS Lett. 1973 Apr 1;31(1):114-8. doi: 10.1016/0014-5793(73)80086-9. FEBS Lett. 1973. PMID: 4709991 No abstract available.
A strong competitive peptide-inhibitor for leucine aminopeptidase.
Jost R, Masson A, Zuber H. Jost R, et al. Among authors: masson a. FEBS Lett. 1972 Jun 15;23(2):211-4. doi: 10.1016/0014-5793(72)80343-0. FEBS Lett. 1972. PMID: 4634438 No abstract available.
The structures of two glucans from yeast-cell walls.
Manners DJ, Masson AJ. Manners DJ, et al. Among authors: masson aj. FEBS Lett. 1969 Jul;4(2):122-124. doi: 10.1016/0014-5793(69)80211-5. FEBS Lett. 1969. PMID: 11947161 No abstract available.
Predictive factors for lumacaftor/ivacaftor clinical response.
Masson A, Schneider-Futschik EK, Baatallah N, Nguyen-Khoa T, Girodon E, Hatton A, Flament T, Le Bourgeois M, Chedevergne F, Bailly C, Kyrilli S, Achimastos D, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Masson A, et al. J Cyst Fibros. 2019 May;18(3):368-374. doi: 10.1016/j.jcf.2018.12.011. Epub 2018 Dec 28. J Cyst Fibros. 2019. PMID: 30595473
CONCLUSION: This observational study investigates a number of potential factors linked to the clinical response of F508del homozygous patients treated with lumacaftor-ivacaftor combination therapy. ...
CONCLUSION: This observational study investigates a number of potential factors linked to the clinical response of F508del homozygous …
Might Brushed Nasal Cells Be a Surrogate for CFTR Modulator Clinical Response?
Pranke I, Hatton A, Masson A, Flament T, Le Bourgeois M, Chedevergne F, Bailly C, Urbach V, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Pranke I, et al. Among authors: masson a. Am J Respir Crit Care Med. 2019 Jan 1;199(1):123-126. doi: 10.1164/rccm.201808-1436LE. Am J Respir Crit Care Med. 2019. PMID: 30326728 No abstract available.
Vaccine coverage in CF children: A French multicenter study.
Masson A, Launay O, Delaisi B, Bassinet L, Remus N, Lebourgeois M, Chedevergne F, Bailly C, Foucaud P, Corvol H, deBlic J, Sermet-Gaudelus I. Masson A, et al. J Cyst Fibros. 2015 Sep;14(5):615-20. doi: 10.1016/j.jcf.2015.04.006. Epub 2015 May 16. J Cyst Fibros. 2015. PMID: 25985911 Clinical Trial.
METHODS: Data were extracted from the "MucoFlu" study, which was a prospective study performed in 2009 in the 5 cystic fibrosis centers of the Paris metropolitan area. ...Coverage for vaccines specifically recommended in CF was low for hepatitis A, non conjugate pne …
METHODS: Data were extracted from the "MucoFlu" study, which was a prospective study performed in 2009 in the 5 cystic fibrosis cente …
[Parapneumonic pleural effusion incidence in a French region before and during the antipneumococcal vaccine era].
Masson A, Ménetrey C, Garnier F, Bahans C, Fargeot A, Layadi M, Soulier JL, Guigonis V. Masson A, et al. Arch Pediatr. 2011 Aug;18(8):846-9. doi: 10.1016/j.arcped.2011.05.010. Epub 2011 Jun 12. Arch Pediatr. 2011. PMID: 21664805 French.
Data from the children hospitalized for parapneumonic pleural effusion were collected for two periods: period A, from July 2000 to July 2006, and period B, from July 2006 to July 2009 (before and after the generalization of the antipneumococcal vaccination). ...RESULTS: …
Data from the children hospitalized for parapneumonic pleural effusion were collected for two periods: period A, from July 2000 to Ju …
385 results
Jump to page
Feedback